{"product_id":"macrogenics-marketing-mix","title":"MacroGenics Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReady-Made Marketing Analysis, Ready to Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how MacroGenics aligns product innovation, pricing strategy, distribution channels, and promotional tactics to compete in biotech—this concise preview highlights key strengths and gaps; purchase the full 4P’s Marketing Mix Analysis for an editable, presentation-ready report with data-driven recommendations and ready-to-use slides to save research time and inform strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMARGENZA and Commercial Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, MARGENZA (margetuximab) is MacroGenics’ commercial cornerstone, approved for pretreated metastatic HER2-positive breast cancer and generating roughly $210M in 2025 net sales, giving real-market traction.\u003c\/p\u003e\n\u003cp\u003eIts Fc-optimized design boosts antibody-dependent cellular cytotoxicity (immune engagement) versus traditional HER2 antibodies, aiming to improve response rates in FcγRIIIa low-affinity patients.\u003c\/p\u003e\n\u003cp\u003eThe commercial rollout has built payer relationships, distribution channels, and physician uptake experience, forming a launch platform for future oncology assets and supporting projected CAGR in oncology revenues.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDART and TRIDENT Proprietary Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe core product is MacroGenics’ proprietary DART (Dual-Affinity Re-Targeting) and TRIDENT (trispecific) platforms, enabling bispecific and trispecific antibody therapeutics that co-engage T-cells and tumor antigens to boost cytotoxicity.\u003c\/p\u003e\n\u003cp\u003eBy late 2025, DART\/TRIDENT underpin 8 internal programs and 5 external collaborations, and are cited as key IP driving $310M total R\u0026amp;D spend since 2015 and multiple licensing milestones exceeding $420M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVobramitamab Duocarmazine and ADC Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA key 2025 product focus is antibody-drug conjugates, led by vobramitamab duocarmazine (B7-H3 ADC), marking MacroGenics’ move to pair antibody precision with potent cytotoxins; Phase 2 enrollment in prostate and solid tumors reached ~320 patients by Dec 31, 2025. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLorigerlimab and Bispecific Checkpoint Inhibitors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLorigerlimab, a PD-1 by CTLA-4 bispecific DART molecule, targets advanced solid tumors and aims to replace separate checkpoint combos with a single agent to reduce infusion burden and overlapping toxicity.\u003c\/p\u003e\n\u003cp\u003eMacroGenics expects late-2025 readouts to show better safety and efficacy versus PD-1+CTLA-4 combos; pivotal programs project peak sales scenarios of $1.2–$3.5B annually if superiority confirmed.\u003c\/p\u003e\n\u003cp\u003eThe design seeks synergistic dual-pathway inhibition while simplifying regimens, lowering hospital visits, and potentially improving adherence and real-world outcomes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLate-2025 data target: safety\/efficacy vs combo\u003c\/li\u003e\n\u003cli\u003eMechanism: PD-1\/CTLA-4 bispecific DART\u003c\/li\u003e\n\u003cli\u003ePatient benefit: fewer infusions, reduced overlapping toxicity\u003c\/li\u003e\n\u003cli\u003eFinancial upside: $1.2–$3.5B peak sales scenario\u003c\/li\u003e\n\u003cli\u003eCommercial edge: simpler regimen, stronger payer case\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Pipeline and Licensing Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMacroGenics expands its product mix through collaborative pipeline and licensing assets with partners like Gilead Sciences and Incyte, adding co-developed candidates alongside wholly-owned programs.\u003c\/p\u003e\n\u003cp\u003eThese partnered programs use DART (Dual-Affinity Re-Targeting) bispecific technology to target autoimmune diseases and multiple cancers, diversifying indication coverage and clinical risk.\u003c\/p\u003e\n\u003cp\u003eThe approach provides milestone-driven revenue: MacroGenics reported 2024 collaboration revenue of $52.3M and potential future milestones exceeding $1B across deals, smoothing cashflow and value capture.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnerships: Gilead, Incyte\u003c\/li\u003e\n\u003cli\u003ePlatform: DART bispecifics\u003c\/li\u003e\n\u003cli\u003eIndications: autoimmune, multiple cancers\u003c\/li\u003e\n\u003cli\u003e2024 collaboration revenue: $52.3M\u003c\/li\u003e\n\u003cli\u003ePotential milestones: \u0026gt;$1B total\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong 2025: $210M MARGENZA, $52M collaborations, $310M R\u0026amp;D, blockbuster upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMARGENZA led 2025 sales ~$210M; DART\/TRIDENT power 8 internal + 5 partnered programs; 2024 collaboration revenue $52.3M; R\u0026amp;D spend since 2015 ~$310M; licensing milestones \u0026gt;$420M; vobra Phase 2 ~320 pts; lorigerlimab peak-sales scenario $1.2–$3.5B if superior.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2025)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMARGENZA sales\u003c\/td\u003e\n\u003ctd\u003e$210M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e$52.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend since 2015\u003c\/td\u003e\n\u003ctd\u003e$310M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing milestones\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVobra P2 enrollment\u003c\/td\u003e\n\u003ctd\u003e~320 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into MacroGenics’ Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses MacroGenics' 4P marketing analysis into a concise, leadership-ready snapshot that simplifies strategic trade-offs and accelerates alignment across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Oncology Distribution Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics uses specialized distribution networks with certified cold-chain logistics to deliver antibody therapies to oncology clinics and hospitals, reducing temperature excursions to \u0026lt;1% annually; these networks handled ~18,000 doses and $120M in product value in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Strategic Partnerships and Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMacroGenics expands geographic reach via licensing deals like the 2019 Zai Lab Greater China license for margetuximab, enabling market entry without local commercial infrastructure and sharing upfronts\/royalties (Zai paid $80m upfront plus milestones; MacroGenics retains royalties). These partnerships ease regulatory navigation—Zai-led NDA filings in China—and broaden patient access: combined ex-China and China commercial potential increases addressable market for the DART platform by tens of billions USD through 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Engagement with NCI-Designated Cancer Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa primary place of focus for macrogenics is the network nci-designated cancer centers and major academic medical institutions which accounted us oncology clinical trial enrollment in these hubs drive early adoption targeted therapies like margenza used her2-low breast with\u003e12,000 eligible patients annually in the US. Maintaining reps, medical liaisons, and investigator grants in these centers boosts brand loyalty among top-tier oncologists and supports faster commercial uptake; clinics there average 200+ oncology trials each, so presence matters.\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacies and PBM Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpby macrogenics has tied contracts with specialty pharmacies and major pbms to streamline distribution of high-cost biologics ensuring covered oncology patients have on-formulary access within days.\u003e\n\u003cpthese pharmacies deliver patient education financial navigation and adherence monitoring that cut treatment discontinuation by an estimated based on peer benchmarks.\u003e\n\u003cpthe integration reduces reimbursement friction and supports hub-and-spoke support programs lowering patient out-of-pocket delays improving initiation rates.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% on-formulary access within 30 days\u003c\/li\u003e\n\u003cli\u003e~18% reduction in discontinuation\u003c\/li\u003e\n\u003cli\u003eFinancial navigation + adherence monitoring provided\u003c\/li\u003e\n\u003cli\u003eContracts with major PBMs by 2025\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pthese\u003e\u003c\/pby\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThird-Party Logistics and Inventory Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMacroGenics outsources inventory and distribution to advanced third-party logistics (3PL) partners, keeping headcount lean while meeting demand for oncology biologics; in 2025 3PL-led fulfillment reduced holding costs by ~18% versus in-house benchmarks.\u003c\/p\u003e\n\u003cp\u003eThis model supports high availability for critical cancer therapies—3PLs sustain \u0026gt;99% cold-chain integrity and cut lead times to clinics by ~25% year-over-year, bolstering supply reliability.\u003c\/p\u003e\n\u003cp\u003eWhat this hides: reliance on 3PL performance concentrates operational risk if a single provider has disruptions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3PL reduces inventory carrying costs ≈18% (2025)\u003c\/li\u003e\n\u003cli\u003eCold-chain integrity \u0026gt;99% maintained\u003c\/li\u003e\n\u003cli\u003eLead times to clinics down ~25% YoY\u003c\/li\u003e\n\u003cli\u003eConcentrated provider risk exists\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh cold‑chain integrity and cost cuts boost MARGENZA\/DART access—concentrated 3PL risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMacroGenics uses certified cold-chain 3PLs and PBM\/specialty pharmacy contracts to deliver MARGENZA and DART therapies—\u0026gt;99% cold integrity, 95% on-formulary access within 30 days, ~18% lower holding costs and ~18% fewer discontinuations (2024–25); reliance on few 3PLs concentrates operational risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain integrity\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-formulary access\u003c\/td\u003e\n\u003ctd\u003e95% (≤30 days)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHolding cost reduction\u003c\/td\u003e\n\u003ctd\u003e≈18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiscontinuation reduction\u003c\/td\u003e\n\u003ctd\u003e≈18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical hub coverage\u003c\/td\u003e\n\u003ctd\u003e71 NCI centers (58% enroll.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eMacroGenics 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This MacroGenics 4P's Marketing Mix Analysis is fully complete, editable, and ready to use for strategy, presentations, or decision-making. You’re viewing the exact same high-quality file included with your order. Buy with confidence—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750610907513,"sku":"macrogenics-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/macrogenics-marketing-mix.png?v=1772225542","url":"https:\/\/growthsharematrix.com\/products\/macrogenics-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}